MADISON, Wis., Nov. 23, 2020 /PRNewswire/ -- Exact Sciences
Corp. (Nasdaq: EXAS) today announced that company management will
participate in the following conference and invited investors to
participate by webcast.
- Evercore ISI HealthCONx Conference
Fireside Chat on Wednesday, December 2,
2020, at 1:00 p.m. EST
The webcast can be accessed in the investor relations section of
Exact Sciences' website at www.exactsciences.com.
About Exact Sciences Corp.
A leading provider of
cancer screening and diagnostic tests, Exact Sciences relentlessly
pursues smarter solutions providing the clarity to take
life-changing action, earlier. Building on the success of Cologuard
and Oncotype DX, Exact Sciences is investing in its product
pipeline to take on some of the deadliest cancers and improve
patient care. Exact Sciences unites visionary collaborators to help
advance the fight against cancer. For more information, please
visit the company's website at www.exactsciences.com, follow Exact
Sciences on Twitter @ExactSciences, or find Exact Sciences on
Facebook.
Forward-Looking Statements
This news release contains
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended, that are intended to
be covered by the "safe harbor" created by those sections.
Forward-looking statements, which are based on certain assumptions
and describe our future plans, strategies and expectations, can
generally be identified by the use of forward-looking terms such as
"believe," "expect," "may," "will," "should," "would," "could,"
"seek," "intend," "plan," "goal," "project," "estimate,"
"anticipate" or other comparable terms. All statements other than
statements of historical facts included in this news release
regarding our strategies, prospects, expectations, financial
condition, operations, costs, plans and objectives are
forward-looking statements. Examples of forward-looking statements
include, among others, statements we make regarding expected future
operating results, anticipated results of our sales, marketing and
patient adherence efforts, expectations concerning payer
reimbursement, the anticipated results of our product development
efforts, the anticipated benefits of the pending acquisition of
Thrive Earlier Detection Corporation ("Thrive"), including
estimated synergies and other financial impacts, and the expected
timing of completion of the transaction. Forward-looking statements
are neither historical facts nor assurances of future performance
or events. Instead, they are based only on current beliefs,
expectations and assumptions regarding the future of our business,
future plans and strategies, projections, anticipated events and
trends, the economy and other future conditions. Because
forward-looking statements relate to the future, they are subject
to inherent uncertainties, risks and changes in circumstances that
are difficult to predict and many of which are outside of our
control. Actual results, conditions and events may differ
materially from those indicated in the forward-looking statements.
Therefore, you should not rely on any of these forward-looking
statements. Important factors that could cause actual results,
conditions and events to differ materially from those indicated in
the forward-looking statements include, among others, the
following: uncertainties associated with the coronavirus (COVID-19)
pandemic, including its possible effects on our operations,
including our supply chain, and the demand for our products and
services; our ability to efficiently and flexibly manage our
business amid uncertainties related to COVID-19; our ability to
successfully and profitably market our products and services; the
acceptance of our products and services by patients and healthcare
providers; our ability to meet demand for our products and
services; the success of our efforts to facilitate patient access
to Cologuard via telehealth; the willingness of health insurance
companies and other payers to cover our products and services and
adequately reimburse us for such products and services; the amount
and nature of competition for our products and services; the
effects of the adoption, modification or repeal of any law, rule,
order, interpretation or policy relating to the healthcare system,
including without limitation as a result of any judicial, executive
or legislative action; the effects of changes in pricing, coverage
and reimbursement for our products and services, including without
limitation as a result of the Protecting Access to Medicare Act of
2014; recommendations, guidelines and quality metrics issued by
various organizations such as the U.S. Preventive Services Task
Force, the American Society of Clinical Oncology, the American
Cancer Society, and the National Committee for Quality Assurance
regarding cancer screening or our products and services; our
ability to successfully develop new products and services and
assess potential market opportunities; our ability to effectively
enter into and utilize strategic partnerships, such as through our
Promotion Agreement with Pfizer, Inc., and acquisitions; our
success establishing and maintaining collaborative, licensing and
supplier arrangements; our ability, and the ability of Thrive, to
maintain regulatory approvals and comply with applicable
regulations; our ability to manage an international business and
our expectations regarding our international expansion and
opportunities; the potential effects of foreign currency exchange
rate fluctuations and our efforts to hedge such effects; the
possibility that the anticipated benefits from our business
acquisitions (including the pending acquisition of Thrive and
recent acquisition of Base Genomics Limited ("Base") cannot be
realized in full or at all or may take longer to realize than
expected; the possibility that costs or difficulties related to the
integration of acquired businesses' operations will be greater than
expected and the possibility of disruptions to our business during
integration efforts and strain on management time and resources;
the outcome of any litigation, government investigations,
enforcement actions or other legal proceedings; our and Thrive's
ability to receive the required the required regulatory approvals
for the pending merger and to satisfy the conditions to the closing
of the transaction on a timely basis or at all; the occurrence of
events that may give rise to a right of one or both of us and
Thrive to terminate the merger agreement; possible negative effects
of the consummation of business acquisition on our acquired
companies' respective businesses, financial conditions, results of
operations and financial performance; significant transaction costs
and/or unknown liabilities; risks associated with potential
transaction-related litigation; our and Thrive's ability to retain
and hire key personnel; and the other risks and uncertainties
described in the Risk Factors and in Management's Discussion and
Analysis of Financial Condition and Results of Operations sections
of our most recently filed Annual Report on Form 10-K and our
subsequently filed Quarterly Reports on Form 10-Q. We undertake no
obligation to publicly update any forward-looking statement,
whether written or oral, that may be made from time to time,
whether as a result of new information, future developments or
otherwise.
Contact:
Megan
Jones
Exact Sciences Corp.
meganjones@exactsciences.com
608-535-8815
View original content to download
multimedia:http://www.prnewswire.com/news-releases/exact-sciences-to-participate-in-december-investor-conference-301178586.html
SOURCE EXACT SCIENCES CORP